Aamir Malik
BLOOMINGTON, Ind. – Aamir Malik, an alumnus of the Indiana University Kelley School of Business, has been named executive vice president and chief business innovation officer of Pfizer Inc., a company known worldwide for its vaccines and for working to end the current COVID-19 pandemic.
Malik, who will be a member of Pfizer’s executive leadership team and report directly to the chairman and CEO, graduated from Kelley with a bachelor’s degree in finance in 1997 and today serves on the school’s Dean’s Council advisory board.
He comes to Pfizer after more than 24 years at McKinsey & Company, where he most recently served as the managing partner responsible for the firm’s U.S. operations. Previously, he led the firm’s global pharmaceuticals and medical products practice.
“We are living at a time of unprecedented scientific advancement, and Pfizer is a company that is unparalleled in its ambition to make a difference in patients’ lives,” Malik told the editor of biopharma news site Endpoints. “For me, there could be no professional opportunity greater than to leverage my diverse experiences across life-sciences to play a role in helping deliver on this aspiration, working alongside a leadership team for whom I have the deepest respect.”
Idalene “Idie” Kesner, dean of the Kelley School and the Frank P. Popoff Chair of Strategic Management, congratulated Malik and noted that his appointment reflects both Kelley’s traditional strengths in thought leadership in consulting and developing key decision makers in healthcare, the life sciences, and the pharmaceutical industry, especially at this time of unprecedented change.
“We’re proud of Aamir’s achievements. His path is just one example of how an innovative business education is valuable in many industries,” Kesner said. “His dedication also is testament to Kelley’s mission to be citizens of the world and to use our talents to affect positive change.”
At Pfizer, Malik will oversee the company’s strategy, business development, portfolio management, pipeline prioritization and formation of new business ventures, as well as the advancement of innovative access partnerships with payers and governments around the world.
He is an active advocate for bettering the lives of people with food allergies and has lived and worked globally including in the U.S., Europe, Asia, Latin America, and Africa. He speaks several languages, including Spanish, Swahili, and Punjabi.
In announcing Malik’s appointment on Aug. 26, Pfizer Chairman and CEO Albert Bourla noted the important role he will play as “we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to re-imagine how we do business for the benefit of patients and society.
“Aamir brings with him 25 years of experience developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs to improve patients’ lives and transform performance for life science companies. He is the ideal leader to drive these efforts,” Bourla added.